

Special Issue

Immunomodulation and Development of Immunotherapies for Human Autoimmunity, Inflammation, Infection, Allergy, and Cancer

Message from the Guest Editors

Both protective and detrimental immune responses are primarily facilitated by T and B cells, which possess enormous diversity in antigen recognition, high antigen specificity, potent effector activity, and long-lasting immunologic memory. A major challenge in immunology and biomedicine is to determine how the unresponsiveness of the adaptive immune system to self-antigens is established and maintained, and how the quality and magnitude of adaptive immune responses to non-self-antigens are controlled to avoid damage to the host. Despite technological advances, treatments for many and inflammatory and autoimmune diseases, primarily rely on broad-spectrum immunosuppressive agents. However, the associated immunosuppressive regimens result in severe side effects, and safer and more effective treatments are thus required. Hence, increasing efforts have focused on developing immunotherapies aimed at targeting the underlying disease process to modulate the immune system, maximize critical cell function, and induce and/or enhance T-reg cells and their function.

- immunomodulation
- immunotherapies
- immune system
- human autoimmunity

Guest Editors

Dr. Nitin Amdare

Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, USA

Dr. Phaneendra K. Duddempudi

Albert Einstein College of Medicine of Yeshiva University, New York, NY, USA

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/157886

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).